Vantage logo

Neptune leaves Astra at sea

The Neptune lung cancer study fails, denting yet further Astrazeneca and Bristol-Myers Squibb’s chances of challenging Merck & Co’s Keytruda on the basis of tumour…

Vantage logo

Where now for Oxurion?

The failure of its lead product in diabetic macular oedema, a limited pipeline and limited cash leaves Oxurion with few options.

Vantage logo

Plan B or bust for Glycomimetics

The failure of its lead sickle cell project forces Glycomimetics to pivot to a leukaemia asset, but the company’s approach has taken a huge blow.